We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Polymeric Strand Replaces Platinum in Aneurysm Coiling Procedures

By HospiMedica International staff writers
Posted on 19 Apr 2011
A novel aneurysm-treatment system will offer physicians an alternative solution to platinum coils in the treatment of large, giant, and wide-neck cerebral aneurysms, which are typically the most challenging to treat.

The cPAX aneurysm-treatment system provides effective embolization of large and giant cerebral aneurysms using an 85-cm long polymeric strand delivered through a microcatheter into a cerebral aneurysm over a guide wire. More...
The soft, flexible material allows for increased packing density, providing conformable filling and increased packing density when compared to platinum coils. The continuous filling capability contributes to a reduction in the amount of devices necessary to complete the procedure, as well as the time required for treatment. Due to its soft polymeric material, it may also provide a more complete filling of the aneurysm and greater long-term stability.

Unlike platinum coils, which have a fixed detachment zone, the cPAX can detach at any point chosen by the clinician. The continuous filling capability of the product also decreases both the number of devices and the amount of time required for treatment. The polymeric material also allows for noninvasive magnetic resonance imaging (MRI) and computed tomography (CT) scans without metallic artifact, allowing for better patient follow-up assessment. The cPAX system, a product of NeuroVASx (Maple Grove, MN, USA), has been approved by the US Food and Drug Administration (FDA) as a humanitarian use device for the treatment of cerebral aneurysms.

"This FDA approval brings an important cutting-edge technology to a patient population that is currently underserved,” said Eric Timko, president and CEO of NeuroVasx. "We are excited to offer this treatment to patients and we look forward to working with our key physicians to bring this product to market.”

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain, which can be caused by several factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use, or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain; approximately 40% of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery using minimally invasive techniques.

Related Links:

NeuroVASx



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.